Prenatal lead exposure and schizophrenia: a plausible neurobiologic connection
- PMID: 15345353
- PMCID: PMC1247541
- DOI: 10.1289/ehp.112-a724a
Prenatal lead exposure and schizophrenia: a plausible neurobiologic connection
Comment on
-
Prenatal lead exposure, delta-aminolevulinic acid, and schizophrenia.Environ Health Perspect. 2004 Apr;112(5):548-52. doi: 10.1289/ehp.6777. Environ Health Perspect. 2004. PMID: 15064159 Free PMC article.
References
-
- Coyle JT, Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology. 2004a;174:32–38. - PubMed
-
- Coyle JT, Tsai G. NMDA receptor function, neuroplasticity, and the pathophysiology of schizophenia. Int Rev Neurobiol. 2004b;59:491–515. - PubMed
-
- Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann NY Acad Sci. 2003;1003:318–327. - PubMed
-
- Hashemzadeh-Gargari H, Guilarte TR. Divalent cations modulate N-methyl-d-aspartare receptor function at the glycine site. J Pharm Exp Ther. 1999;290:1356–1362. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical